Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia

BACKGROUND: Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed feasibility and early efficacy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia (r/r T-ALL), in a previous phase I trial report, at a median follow-up of 6.3 months. Here we report long-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Yue, Shan, Lingling, Zhao, Liping, Deng, Biping, Ling, Zhuojun, Zhang, Yanlei, Peng, Shuixiu, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Yu, Xinjian, Zheng, Qinlong, Xu, Xiuwen, Tian, Zhenglong, Zhang, Yibing, Zhang, Jiecheng, Chang, Alex H., Feng, Xiaoming, Pan, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074659/
https://www.ncbi.nlm.nih.gov/pubmed/37020231
http://dx.doi.org/10.1186/s13045-023-01427-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074659/
https://www.ncbi.nlm.nih.gov/pubmed/37020231
http://dx.doi.org/10.1186/s13045-023-01427-3

Ejemplares similares